Compare REGN & PCAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | PCAR |
|---|---|---|
| Founded | 1988 | 1905 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 70.1B |
| IPO Year | 1995 | 2010 |
| Metric | REGN | PCAR |
|---|---|---|
| Price | $796.95 | $131.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 25 | 10 |
| Target Price | ★ $830.16 | $118.11 |
| AVG Volume (30 Days) | 764.3K | ★ 3.6M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | 0.55% | ★ 2.30% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 18.95 | 2.57 |
| Revenue | $5,872,227,000.00 | ★ $28,444,800,000.00 |
| Revenue This Year | $12.45 | $2.75 |
| Revenue Next Year | $10.13 | $9.41 |
| P/E Ratio | ★ $42.06 | $51.57 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $541.00 | $92.25 |
| 52 Week High | $821.11 | $139.24 |
| Indicator | REGN | PCAR |
|---|---|---|
| Relative Strength Index (RSI) | 77.83 | 53.75 |
| Support Level | $738.17 | $129.78 |
| Resistance Level | $818.06 | $139.24 |
| Average True Range (ATR) | 21.79 | 4.01 |
| MACD | 7.78 | -0.62 |
| Stochastic Oscillator | 91.45 | 16.14 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Paccar is a leading manufacturer of medium- and heavy-duty trucks under the premium nameplates Kenworth and Peterbilt, which are primarily sold in the Americas and Australia, and DAF, which primarily services Europe and South America. The trucks segment (74% sales) goes to market through a network of 2,200 independent dealers. Paccar maintains an internal finance subsidiary that provides retail and wholesale financing for customers and dealers (6% sales). In recent years, Paccar has aggressively expanded its parts business (20% of sales), including engines, axles, and transmissions for its own truck brands as well as independent producers. The company commands 30% of the Class 8 market share in North America and 15% of the heavy-duty market share in Europe.